

25. (New) An immunogenic composition comprising the polypeptide fragment of claim 23.

26. (New) An immunogenic composition comprising the polypeptide fragment of claim 24.

27. (New) A polypeptide fragment,
wherein said polypeptide fragment binds to antibodies in LAS patient sera, and
wherein said polypeptide fragment comprises an HIV-1_{ELI} epitope that does not react with
antibodies directed against specific epitopes of HIV-1_{IIIB}, HIV-1_{BRU}, or HIV-1_{ARV-2}.

28. (New) The polypeptide fragment of claim 27, wherein said polypeptide fragment
comprises 5-150 amino acid residues.

29. (New) An immunogenic composition comprising the polypeptide fragment of
claim 27.

30. (New) An immunogenic composition comprising the polypeptide fragment of
claim 28. --

REMARKS

Claims 1 has been canceled. Claims 80-87 are new and are fully supported by the
specification, for example, on pages 28 and 32. No new matter enters by amendment.

Applicants submit that this application is now in condition for allowance. If the
Examiner should disagree, he is invited to contact the undersigned to discuss any remaining
issues.

LAW OFFICES

FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000